Alzheimer’s disease (AD) is characterized by deposition of amyloid-β protein aggregates
and an appropriate treatment strategy is urgently needed, as the number of diagnosed cases continues
to increase. The management of AD and other brain-associated diseases is limited by the blood brain
barrier and its selective control of drug passage. In fact, most of the promising drugs have restricted
curative effects on AD owing to their lower bioavailability. Gold nanoparticles (AuNPs) have emerged
as attractive therapeutic agents and have distinctive properties that could contribute to the development
of a novel treatment strategy for neurodegenerative disorders. In this review article, we attempt to identify
promising ways of developing competent AD therapeutic agents from anti-amyloid aggregating
AuNPs. Initially, we discuss the current status of anti-amyloid inhibitors, the abilities of AuNPs to
inhibit amyloid aggregation, and mechanistic aspects, and then describe plausible modifications that
could aid the translation of AuNP-based therapeutics into neuromedicines. The review highlights some
interesting characteristics that might effectively bridge the gap between laboratory and bedside treatments.
Keywords: Alzheimer`s disease, amyloid-β, blood-brain barrier, nanoparticles, neurodegenerative disorders, gold.
Rights & PermissionsPrintExport